HIV type 1 alters mesenchymal stem cell differentiation potential and cell phenotype ex vivo

AIDS Research and Human Retroviruses

Volumn 27, Issue 2, 2011, Pages 187-199

  Cotter, Eoin J ^a   Chew, Nicholas ^a   Powderly, William G ^a   Doran, Peter P ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD4 ANTIGEN; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 1; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PYRIDOXAL 5 PHOSPHATE; TRANSACTIVATOR PROTEIN; ZIDOVUDINE;

ADIPOCYTE; ADIPOGENESIS; ADULT; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; MESENCHYMAL STEM CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; VIRUS ATTENUATION; VIRUS LOAD;

CELL DIFFERENTIATION; HIV INFECTIONS; HIV-1; HUMANS; MESENCHYMAL STEM CELLS; PHENOTYPE; VIRAL LOAD;

EID: 79951688708     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0114     Document Type: Article

References (41)

1. Brown TT and Qaqish RB: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS 2006;20:2165-2174. (Pubitemid 44684707)
2. Knobel H, Guelar A, Vallecillo G, Nogués X, and Díez A: Osteopenia in HIV-infected patients: Is it the disease or is it the treatment? AIDS 2001;15:807-808. (Pubitemid 32423234)
3. Millinkovic A: HIV-associated lipodystrophy syndrome. Coll Antropol 2006;Suppl 2:59-62.
4. Mallon PW, Miller J, Cooper DA, and Carr A: Prospective evaluation of antiretroviral therapy in HIV-1-infected men starting therapy. AIDS 2003;17:971-979. (Pubitemid 36549708)
5. Caplan AI: Mesenchymal stem cells. J Ortho Res 2001;9: 641-650.
6. Gregory CA, Prockop DJ, and Spees JL: Non-hematopoietic bone marrow stem cells: Molecular control of expansion and differentiation. Exp Cell Res 2005;306:330-335. (Pubitemid 40732757)
7. Nuttall ME and Gimble JM: Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharm 2004;4: 290-294. (Pubitemid 38585315)
8. Meunier P, Aaron J, Edouard C, and Vignon G: Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res 1979;80:147-154.
9. Beresford JN, Bennett JH, Devlin C, Leboy PS, and Owen ME: Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci 1992;102(Pt 2):341-351.
10. Dorheim MA, Sullivan M, Dandapani V, Wu X, Hudson J, et al.: Osteoblastic gene expression during adipogenesis in hematopoietic supporting murine bone marrow stromal cells. J Cell Physiol 1993;154:317-328. (Pubitemid 23048013)
11. Verma S, Rajaratnam JH, Denton J, Hoyland JA, and Byers JR: Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol 2002;55(9):693-698. (Pubitemid 34970093)
12. Gimble JM, Morgan C, Kelly K, Wu X, Dandapani V, et al.: Bone morphogenetic proteins inhibit adipocyte differentiation by bone marrow stromal cells. J Cell Biochem 1995; 58:393-402.
13. Hamrick MW: Invited perspective: Leptin and bone-a consensus emerging? Bonekey Osteovision 2007;4:99-107.
14. Hamrick MW, Della-Fera MA, Choi YH, Pennington C, Hartzell D, et al.: Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptindeficient ob/ob mice. J Bone Miner Res 2005;20(6):994-1001. (Pubitemid 40712824)
15. Gimble JM, Zvonic S, Floyd ZE, Kassem M, and Nuttall ME: Playing with bone and fat. J Cell Biochem 2006;98(2): 251-266.
16. Zhao LJ, Jiang H, Papasian CJ, Maulik D, Drees B, et al.: Correlation of obesity and osteoporosis: Effect of fat mass on the determination of osteoporosis. J Bone Miner Res 2008; 23(1):17-29.
17. Shi X, Hamrick M, and Isales CM: Energy balance, myostatin, and GILZ: Factors regulating adipocyte differentiation in belly and bone. PPAR Res 2007;92:501.
18. Lazarenko OP, Rzonca SO, Suva LJ, and Lecka-Czernik B: Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 2005;38(1):74-78.
19. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, et al.: Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226-1235. (Pubitemid 40289310)
20. Akune T, Ohba S, Kamekura S, Chung UI, Kubota N, et al.: PPARg insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004;113(6):846-855. (Pubitemid 38544143)
21. Kim SH, Yoo CI, Kim HT, Park JY, Kwon CH, et al.: Activation of perosisome proliferator-activated receptor-gamma (PPARgamma) induces death through MAPK-dependent mechanism in osteoblastic cells. Toxicol Appl Pharmacol 2006;215(2):198-207. (Pubitemid 44190007)
22. Wang L, Mondal D, La Russa VF, and Agrawal KC: Suppression of clonogenic potential of human bone marrow mesenchymal stem cells by HIV type 1; putative role of HIV type 1 Tat protein and inflammatory cytokines. AIDS Res Hum Retroviruses 2002;18(13):917-931.
23. Cotter EJ, Ip HSM, Powderly WG, and Doran PP: Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. BMC Muscl Skel Disord 2008;13(9):33.
24. Jain RG and Lenhard JM: Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem 2002; 277(22):19247-19250. (Pubitemid 34967427)
25. Kaul M, Garden GA, and Lipton SA: Pathways to neuronal injury and apoptosis in HIV-1 associated dementia. Nature 2001;410:988-994. (Pubitemid 32335850)
26. Guo L, Heinzinger NK, Stevenson M, Schopfer LM, and Salhany JM: Inhibition of gp120-CD4 interaction and human immunodeficiency virus type 1 infection in vitro by pyridoxal 5'-phosphate. Antimicrob Agents Chemother 1994; 38(10):2483-2487. (Pubitemid 24304255)
27. Craig DH, Gayer CP, Schaubert KL, Wei Y, Li J, et al.: Increased extracellular pressure enhances cancer cell integrinbinding affinity through phosphorylation of beta1-integrin at threonine 788/789. Am J Physiol Cell Physiol 2009;C193- 204. Epub 2008 Nov 12.
28. Yee KW, O'Farrell AM, Smolich BD, Cherrington JM, McMahon G, et al.: SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 2002;100(8):2941-2949.
29. Ou XM, Li WC, Liu DS, Li YP, Wen FQ, et al.: VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. Int Immunopharmacol 2009;9(1):70-79.
30. Fakruddin JM and Laurence J: HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kB ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferong/ RANKL cross-talk. J Biol. Chem 2003;278:48251-48258. (Pubitemid 37523280)
31. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem 1987;162:156-159. (Pubitemid 17064313)
32. O'Doherty U, Swiggard WJ, Jeyakumar D, McGain D, and Malim MH: A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J Virol 2002;76(21): 10942-10950. (Pubitemid 35176211)
33. Cotter EJ, Malizia AP, Chew N, Powderly WG, and Doran PP: HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses 2007;23(12): 1521-1530.
34. Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H, Huang W, Squires K, Verlinghieri G, and Zhang H: Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 2007;13(10):1241-1247. (Pubitemid 47530631)
35. Scheideler M, Elabd C, Zaragosi LE, Chiellini C, Hackl H, et al.: Comparative transcriptomics of human multipotent stem cells during adipogenesis and osteoblastogenesis. BMC Genomics 2008;17(9):340.
36. Rohr O, Schwartz C, Hery C, Aunis D, Tardieu M, et al.: The nuclear receptor chicken ovalbumin upstream promoter transcription factor interacts with HIV-1 Tat and stimulates viral replication in human microglial cells. J Biol Chem 2000;28(4):2654-2660. (Pubitemid 30082033)
37. Xu Z, Yu S, Hsu CH, Eguchi J, and Rosen ED: The orphan nuclear receptor chicken ovalbumin upstream promoter- transcription factor II is a critical regulator of adipogenesis. Proc Natl Acad Sci USA 2008;105(7):2421-2426. (Pubitemid 351520529)
38. Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, et al.: The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med 1996;2(12):1371-1375. (Pubitemid 26401742)
39. Barillari G, Sgadari C, Fiorelli V, Samaniego F, Colombini S, et al.: The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood 1991;94(2):663-672.
40. Triant VA, Brown TT, Lee H, and Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)- infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008;93(9):3499-3504.
41. Richardson J, Hill AM, Johnston CJ, McGregor A, Norrish AR, Eastwood D, and Lavy CB: Fracture healing in HIVpositive populations. J Bone Joint Surg Br 2008;90(8):988-994.